RDY Q2 Earnings & Revenues Miss Estimates as Lenalidomide Sales Fall

What happened

Dr. Reddy's Laboratories reported second-quarter fiscal 2027 earnings of 12 cents per American Depositary Share, missing the 16-cent estimate. Revenue fell 1.5% to $905 million from $919 million and missed the $981 million estimate, as lower North America lenalidomide sales weighed on results.

Confirmed

Global impact / market context

Lenalidomide is a key generic medicine whose falling sales cut into profit even though the rest of the business grew at a double-digit rate. Investors may question how quickly newer generic launches can replace that lost revenue and restore earnings growth.

Analyst inference

The company's North America generics revenue fell 23% year over year, while India and emerging markets performed better. This shows reliance on a single product in one region can make results uneven, even when the broader product portfolio is expanding.

Analyst inference

What to watch

1. Dr. Reddy's introduced six products during the quarter, including a first-to-market launch, which means a product launched before competitors. Watch whether these new products lift future revenue. Confirmed
2. Watch whether the base business, excluding lenalidomide, keeps growing at a double-digit rate, since that would show new launches are replacing lost sales from the older product. Proposed
3. Monitor North America generics revenue, which fell 23% to INR 24.89 billion, because further declines in lenalidomide sales could pressure overall revenue and profit per sale. Analyst inference

Evidence

• zacks.com